USC Chirurgia Generale III
Welcome,         Profile    Billing    Logout  
 32 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rambaldi, Alessandro
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
NCT01761968 / 2012-003499-37: Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Active, not recruiting
2
90
Europe
givinostat, givinostat (ITF2357)
Italfarmaco
Chronic Myeloproliferative Neoplasms
12/26
12/26
MKIA-088-001, NCT03922100 / 2018-002793-47: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Terminated
1/2
63
Europe
NMS-03592088
Nerviano Medical Sciences
Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
08/24
08/24
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/25
12/28
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Pinna, Antonio Daniele
NCT05045794: Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation

Completed
N/A
219
US
VitaSmart Liver Machine Perfusion System, VitaSmart Liver Machine, Hypothermic oxygenated perfusion, Static cold storage
Bridge to Life Ltd.
End Stage Liver DIsease, Liver Failure
06/24
06/24
Colledan, Michele
No trials found
Velati, Claudio
No trials found
Zambelli, Marco
No trials found

Download Options